A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns.
Joan T MerrillJoel GuthridgeMiles SmithJoshua JuneFotios KoumpourasWambui MachuaAnca D AskanaseArezou KhosroshahiSaira Z SheikhGaurav RathiBart BuringtonPaul FosterMark MatijevicSujata AroraXiaodong WangMinggeng GaoStephen WaxJudith A JamesDebra J ZackPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Although the primary endpoint was not reached, secondary analysis showed time to LOI was significantly increased in obexelimab-treated patients, and analysis of patient subsets defined by gene expression patterns at baseline suggests a responding subpopulation.
Keyphrases
- placebo controlled
- gene expression
- double blind
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- poor prognosis
- dna methylation
- phase iii
- phase ii
- peritoneal dialysis
- open label
- clinical trial
- prognostic factors
- randomized controlled trial
- case report
- squamous cell carcinoma
- peripheral blood
- binding protein
- long non coding rna
- transcription factor
- locally advanced